Health · Medical Research · 1 hr ago

Drug combination cleared tumors and triggered lasting protection in mice

Drug combination cleared tumors and triggered lasting protection in mice

Researchers at Regeneron tested a cancer drug with an experimental antibody in mice with engineered breast or colorectal tumors.

The drug, Enhertu, carries a cell-killing payload to tumor cells with the HER2 protein, while the antibody is designed to help immune cells attack.

Together, the treatments cleared breast tumors in all nine mice that received them, compared with fewer than half responding to the drug alone at the highest tested dose.

After staying tumor-free for at least four weeks, the mice rejected the same breast cancer cells without more treatment.

They did not resist a different colorectal tumor that also carried HER2, suggesting their immune systems recognized other features of the original cancer.

Removing CD8 T cells eliminated the combination’s benefit, showing those cells were essential to the result.

The findings are from mice, while one experimental antibody is already in early-stage human trials; the study does not establish whether these combinations will work in people.

1 source

Related